Ken Griffin Alkermes Plc. Call Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Call Options
8 transactions
Others Institutions Holding ALKS
# of Institutions
346Shares Held
183MCall Options Held
209KPut Options Held
89.4K-
Black Rock Inc. New York, NY29.1MShares$807 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA20MShares$555 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA14.4MShares$398 Million0.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11MShares$305 Million0.03% of portfolio
-
State Street Corp Boston, MA9.22MShares$256 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.56B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...